Hematology · Vitamin KRegulatory Approvalcommercialnear-term

FDA Grants AP Status for Dr. Reddy's PHYTONADIONE ANDA215820

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Dr. Reddy's6 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 12:32:10 AM

Assessment confidence: 65% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of Abbreviated Approval status to Dr. Reddy's for PHYTONADIONE introduces a new competitor in the vitamin K market. This could lead to pricing pressures and shifts in market share, necessitating strategic adjustments from existing players. Regulatory context from FDA (FDA AP — FINASTERIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Dr. Reddy's entry on pricing and market share for existing PHYTONADIONE products. The strongest clinical anchor is Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Approval for Enlicitide by Merck Sharp and Dohme (Humanexa Signals) — sponsor/company relevance (merck). This approval allows Dr. Reddy's to enter the market for PHYTONADIONE, potentially increasing competition in the vitamin K space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FINASTERIDE (SUPPL) (FDA). Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.

Key Opportunities

The entry of Dr. Reddy's into the PHYTONADIONE market may affect revenue streams for current suppliers, as increased competition could lead to price reductions and market share erosion.
Portfolio teams should assess the impact of Dr. Reddy's entry on pricing and market share for existing PHYTONADIONE products.

What Would Change This Assessment

This becomes more urgent if Monitor the launch timeline and market response to Dr. Reddy's PHYTONADIONE product.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREDNISONE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FENOFIBRIC ACID (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
E-cigarette Social Media Marketing and Its Perceptions by Youth
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Menstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Post-marketing Observational Study of Oral Cholera Vaccine
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Approval for Enlicitide by Merck Sharp and Dohme
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)

Dual-mechanism vitamin C delivery by polyethylene glycol-23 glyceryl distearate-based niosomes via SVCT2 induction and enhanced transdermal penetration.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Dr. Reddy's
PHYTONADIONE
market competitors

Commercial impact

medium

The entry of Dr. Reddy's into the PHYTONADIONE market may affect revenue streams for current suppliers, as increased competition could lead to price reductions and market share erosion.

Regulatory impact

low

The approval status indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.

What to watch

Monitor the launch timeline and market response to Dr. Reddy's PHYTONADIONE product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.